National Institutes of Health: Sarcoma, Alveolar Soft Part trials

The registry lists 11 Sarcoma, Alveolar Soft Part studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 2Phase 2 9Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingNCT05333458Phase 2
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/3Results posted
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• Sunitinib or Cediranib for Alveolar Soft Part SarcomaCompletedNCT01391962Phase 2Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part SarcomaCompletedNCT00942877Phase 2Results posted
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
• Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part SarcomaActive, not recruitingNCT03141684Phase 2
• Collection of Alveolar Soft Part Sarcoma and Blood Specimens for ResearchCompletedNCT00340353